Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Keenova Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Narrows

Keenova Therapeutics reported net sales of $549.5 million for the quarter ended September 30, 2026, a significant increase from $416.1 million in the prior year. Despite higher revenue, the company recorded a net loss of $96.1 million for the quarter and $430.1 million for the nine-month period, primarily driven by a $150.6 million loss on divestiture and $207.7 million in non-restructuring impairment charges.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue549.5416.1
Gross profit335.1172.4
Profit before tax-116.1-266.4
Net income-96.1-291.1
EPS (diluted, $ a share)$-2.43$-9.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+32.1%
Gross margin61.0%
Operating margin13.7%
Source

10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Keenova Therapeutics plc: key numbers

Shares outstanding
39.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Keenova Therapeutics plc

All →
4:31 PM ET Form 4
Insider Buying

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $13.7M of Stock

Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).

Value
$13.7M
Shares
150,652
Average price
$90.65
Holding change
+1.4%
Trade date
Nov 9, 2026 to Nov 10, 2026
6:37 AM ET 8-K
Financial Results

Keenova Therapeutics Financial Results

Keenova Therapeutics reported Q3 2026 net sales of $550 million, driven by strong performance from core brands Acthar Gel and XIAFLEX. The company raised its full-year guidance for net sales and Adjusted EBITDA based on higher growth expectations for XIAFLEX and continued demand for Acthar Gel.

Term
Q3 2026

“On this day last year, Keenova introduced itself as a new company with a new identity and a bright future. Since that day, we have made significant strategic, commercial, operational, and clinical progress toward fulfilling our goal of becoming a pure-play branded therapeutics company. Our third-quarter 2026 results further demonstrate the consistent progress we are making against that goal.”

Siggi Olafsson, Board Chair and Chief Executive Officer

“In the quarter our core brands, Acthar Gel and XIAFLEX, contributed better-than-expected performance, driven primarily by increased demand and improved operational execution. As a result, we are reiterating our full-year net sales growth outlook for Acthar Gel of 20% to 22% and now expect XIAFLEX net sales to grow 10% to 11% year over year.”

Siggi Olafsson, Board Chair and Chief Executive Officer
5:30 PM ET Form 4
Insider Buying

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $26.4M of Stock

Goldentree Asset Management LP bought 295,716 shares of Keenova Therapeutics plc at $89.25 a share, worth $26.4M in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 8,875,543 (+1.7%).

Value
$26.4M
Shares
295,716
Average price
$89.25
Holding change
+1.7%
Trade date
Nov 5, 2026 to Nov 6, 2026
4:30 PM ET Form 4
Insider Buying

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $12.3M of Stock

Goldentree Asset Management LP bought 137,000 shares of Keenova Therapeutics plc at $90.00 a share, worth $12.3M in total on Oct 14, 2026. Shares held after the trade: 8,579,827 (+1.6%).

Value
$12.3M
Shares
137,000
Price
$90.00
Holding change
+1.6%
Trade date
Oct 14, 2026
4:30 PM ET Form 4
Insider Buying

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $42.1M of Stock

Goldentree Asset Management LP bought 463,000 shares of Keenova Therapeutics plc at $91.00 a share, worth $42.1M in total on Sep 24, 2026. Shares held after the trade: 8,442,827 (+5.8%).

Value
$42.1M
Shares
463,000
Price
$91.00
Holding change
+5.8%
Trade date
Sep 24, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.